Thyrotropin Receptor Autoantibody Assessment in Thyroid Eye Disease: Does the Assay Type Matter?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Thyroid receptor antibodies can quantify thyroid eye disease activity, predict outcomes and aid timing of interventions. The type and generation of assay is frequently unspecified, complicating meta-analyses. To determine the clinical andbiochemical relationships between a second-generation thyrotropin receptor-binding inhibition antibody (TRAb) immunoassay,detecting stimulatory and blocking antibodies, with the thyroid stimulating immunoglobulin (TSI) bridging immunoassaydetecting the stimulatory component only. Methods: Retrospective review of 100 consecutive patients attending a regional specialist service. For each patient and visit,both a TRAb and TSI were performed, and a clinical activity score (CAS) recorded. Results: A significant positive correlation between TRAb and TSI (rho = 0.828, p < 0.01) but a weaker correlation betweenthe assays and CAS (TRAb: rho = 0.439, p < 0.01; TSI: r = 0.357, p < 0.01) were found. In 10% of the episodic data, patientshad a TRAb level that was disproportionately high (39.41 ± 52.84 IU/L), compared to their TSI levels (9.53 ± 12.10 IU/L) with ahigher-than-average CAS (2.47 ± 1.78; range, 0–5). Within 12 months of diagnosis, a significant positive correlation betweenCAS and TRAb (rho = 0.503, p < 0.01) as well as between CAS and TSI (rho = 0.329, p < 0.01) were found. In patients with adiagnosis over 12 months, the correlation with CAS for both TSI and TRAb were Spearman rank correlation coefficient of 0.347(p < 0.01) and 0.327 (p < 0.01), respectively. Conclusions: TRAb and TSI correlate strongly and to a lesser extent with the CAS. For most patients, TRAb can be replacedwith the more economical TSI. TRAb also correlates better with newly diagnosed, more active patients than TSI. In a subsetof patients, blocking antibodies may play a significant pathogenic role, requiring different treatment and monitoring. Furtherstudies are required to investigate this relationship.
Abstract
Purpose: Thyroid receptor antibodies can quantify thyroid eye disease activity, predict outcomes and aid timing of interventions. The type and generation of assay is frequently unspecified, complicating meta-analyses. To determine the clinical andbiochemical relationships between a second-generation thyrotropin receptor-binding inhibition antibody (TRAb) immunoassay,detecting stimulatory and blocking antibodies, with the thyroid stimulating immunoglobulin (TSI) bridging immunoassaydetecting the stimulatory component only. Methods: Retrospective review of 100 consecutive patients attending a regional specialist service. For each patient and visit,both a TRAb and TSI were performed, and a clinical activity score (CAS) recorded. Results: A significant positive correlation between TRAb and TSI (rho = 0.828, p < 0.01) but a weaker correlation betweenthe assays and CAS (TRAb: rho = 0.439, p < 0.01; TSI: r = 0.357, p < 0.01) were found. In 10% of the episodic data, patientshad a TRAb level that was disproportionately high (39.41 ± 52.84 IU/L), compared to their TSI levels (9.53 ± 12.10 IU/L) with ahigher-than-average CAS (2.47 ± 1.78; range, 0–5). Within 12 months of diagnosis, a significant positive correlation betweenCAS and TRAb (rho = 0.503, p < 0.01) as well as between CAS and TSI (rho = 0.329, p < 0.01) were found. In patients with adiagnosis over 12 months, the correlation with CAS for both TSI and TRAb were Spearman rank correlation coefficient of 0.347(p < 0.01) and 0.327 (p < 0.01), respectively. Conclusions: TRAb and TSI correlate strongly and to a lesser extent with the CAS. For most patients, TRAb can be replacedwith the more economical TSI. TRAb also correlates better with newly diagnosed, more active patients than TSI. In a subsetof patients, blocking antibodies may play a significant pathogenic role, requiring different treatment and monitoring. Furtherstudies are required to investigate this relationship.
참고문헌 (41)
- Roos JCP, "Update on the clinical assessment and management of thyroid eye disease", Curr Opin Ophthalmol, 30, pp.401~406 (2019)
- Wang Y, "Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy", Invest Ophthalmol Vis Sci, 55, pp.1735~1748 (2014)
- Starkey KJ, "Adipose thyrotrophin receptor expression is elevated in Graves’ and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo", J Mol Endocrinol, 30, pp.369~380 (2003)
- Konuk O, "Graves’ orbitopathy: a multidisciplinary approach:questions and answers", pp.74~92 (2017), Karger
- Salvi M, "Graves’ orbitopathy:a multidisciplinary approach: questions and answers", pp.41~60 (2017), Karger
- Ponto KA, "Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy", Ophthalmology, 118, pp.2279~2285 (2011)
- 장선영, "Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves’ Orbitopathy", Yonsei Medical Journal, 54(4), pp.1033~1039 (2013), 연세대학교의과대학[DOI]
- Gerding MN, "Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy", Clin Endocrinol(Oxf), 52, pp.267~271 (2000)
- Eckstein AK, "Thyrotropin receptor autoantibodies are independent risk factors for Graves’ophthalmopathy and help to predict severity and outcome of the disease", J Clin Endocrinol Metab, 91, pp.3464~3470 (2006)
- Lantz M, "Increased TRAb and", or low anti-TPO titers at diagnosis of Graves’disease are associated with an increased risk of developing ophthalmopathy after onset, 2014, pp.122, 113~117
- Khoo DH, "The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy", Thyroid, 9, pp.1175~1180 (1999)
- Roos JC, "Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy", Eye(Lond), 33, pp.212~217 (2019)
- Lehmann GM, "Immune mechanisms in thyroid eye disease", Thyroid, 18, pp.959~965 (2008)
- Feldon SE, "Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy", Invest Ophthalmol Vis Sci, 46, pp.3913~3921 (2005)
- Kuriyan AE, "Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype", Invest Ophthalmol Vis Sci, 54, pp.7370~7377 (2013)
- Diana T, "Stimulatory TSH-receptor antibodies and oxidative stress in Graves disease", J Clin Endocrinol Metab, 103, pp.3668~3677 (2018)
- Zhang L, "Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts : contributory role in hyaluronan accumulation in thyroid dysfunction", J Biol Chem, 284, pp.26447~26455 (2009)
- Valyasevi RW, "Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts", J Clin Endocrinol Metab, 87, pp.2352~2358 (2002)
- Khong JJ, "Pathogenesis of thyroid eye disease : review and update on molecular mechanisms", Br J Ophthalmol, 100, pp.142~150 (2016)
- Rundle FF, "Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy", Clin Sci, 5, pp.177~194 (1945)
- Bartley GB, "Rundle and his curve", Arch Ophthalmol, 129, pp.356~358 (2011)
- Menconi F, "Spontaneous improvement of untreated mild Graves’ ophthalmopathy : rundle’s curve revisited", Thyroid, 24, pp.60~66 (2014)
- Davies TF, "Thyrotropin receptor-associated diseases : from adenomata to Graves disease", J Clin Invest, 115, pp.1972~1983 (2005)
- Kotwal A, "Thyrotropin receptor antibodies : an overview", Ophthalmic Plast Reconstr Surg, 34(4S Suppl 1), pp.S20~7 (2018)
- Tan K, "Lack of standardized description of TRAb assays", Endocrine, 43, pp.732~733 (2013)
- Ehlers M, "TSH-receptor autoantibodies:pathophysiology, assay methods, and clinical applications", Minerva Endocrinol, 43, pp.323~332 (2018)
- Saric-Matutinovic M, "Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy", J Med Biochem, 41, pp.211~220 (2022)
- Tozzoli R, "Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease", Clin Chem Lab Med, 55, pp.58~64 (2017)
- Mourits MP, "Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy", Clin Endocrinol(Oxf), 47, pp.9~14 (1997)
- Das T, "T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study", Eye(Lond), 33, pp.235~243 (2019)
- Diana T, "Thyroid stimulating hormone receptor antibodies in thyroid eye disease-methodology and clinical applications", Ophthalmic Plast Reconstr Surg, 34(4S Suppl 1), pp.S13~9 (2018)
- Jang SY, "Clinical characteristics of Graves’ orbitopathy in patients showing discrepancy between levels from TBII assays and TSI bioassay", Clin Endocrinol(Oxf), 80, pp.591~597 (2014)
- 우영재, "Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves’ Orbitopathy", Korean Journal of Ophthalmology, 29(4), pp.213~219 (2015), 대한안과학회
- Eckstein AK, "Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy", Br J Ophthalmol, 93, pp.1052~1056 (2009)
- Takasu N, "Changes of TSH-stimulation blocking antibody(TSBAb)and thyroid stimulating antibody(TSAb)over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive Graves’ patients with hyperthyroidism : reevaluation of TSBAb and TSAb in TSH-receptor-antibody(TRAb)-positive patients", J Thyroid Res, 2012, pp.182176~ (2012)
- Seo S, "Usefulness of TSH receptor antibodies as biomarkers for Graves’ ophthalmopathy : a systematic review", J Endocrinol Invest, 41, pp.1457~1468 (2018)
- Boschi A, "Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy", Br J Ophthalmol, 89, pp.724~729 (2005)
- McLachlan SM, "Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies : potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa", Thyroid, 23, pp.14~24 (2013)
- Noh JY, "Thyroid-stimulating antibody is related to Graves’ ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease", Thyroid, 10, pp.809~813 (2000)
- Eckstein AK, "Clinical results of anti-inflammatory therapy in Graves’ ophthalmopathy and association with thyroidal autoantibodies", Clin Endocrinol(Oxf), 61, pp.612~618 (2004)
- Chng CL, "Ethnic differences in the clinical presentation of Graves’ ophthalmopathy", Best Pract Res Clin Endocrinol Metab, 26, pp.249~258 (2012)